J. Chaddock

发表

Botulinum Neurotoxin A and Neurotoxin E Cleavage Products of Synaptosome-Associated Protein of 25 kd Exhibit Distinct Actions on Pancreatic Islet &bgr;-Cell Kv2.1 Channel Gating

C. Elias, Y. Leung, Youhou Kang, 2008, Pancreas.

The structure and function of ribosome-inactivating proteins

M. Hartley, J. Chaddock, M. Bonness, 1996 .

Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

K. Acharya, J. Chaddock, K. Turton, 2002, Trends in biochemical sciences.

Engineered botulinum neurotoxins as new therapeutics.

K. Acharya, G. Masuyer, K. Foster, 2014, Annual review of pharmacology and toxicology.

Engineering botulinum neurotoxin domains for activation by toxin light chain

K. Acharya, I. Birch-Machin, G. Masuyer, 2012, The FEBS journal.

Structures of engineered Clostridium botulinum neurotoxin derivatives.

K. Acharya, G. Masuyer, J. Chaddock, 2011, Acta crystallographica. Section F, Structural biology and crystallization communications.

Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain

A. Dickenson, C. Quinn, R. Suzuki, 2002, Movement disorders : official journal of the Movement Disorder Society.

Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A.

K. Acharya, N. Thiyagarajan, G. Masuyer, 2009, Biochemical and biophysical research communications.

Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.

J. Marks, K. Foster, J. Chaddock, 2004, Journal of immunological methods.

Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.

K. Acharya, G. Masuyer, J. Chaddock, 2011, Journal of structural biology.

Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinumToxin A Endopeptidase Fragment and Erythrina cristagalliLectin*

A. Dickenson, C. Quinn, R. Suzuki, 2002, The Journal of Biological Chemistry.

Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A.

C. Quinn, C. Shone, K. Foster, 2002, Protein expression and purification.

Clostridial neurotoxins: structure-function led design of new therapeutics

J. Chaddock, P. Marks, P. Marks, 2006, Cellular and Molecular Life Sciences.

Transforming the domain structure of botulinum neurotoxins into novel therapeutics.

J. Chaddock, 2013, Current topics in microbiology and immunology.

Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics

D. Rogers, C. Cruttwell, C. Shone, 2006, Neurotoxicity Research.

Addition of an ER retention signal to the ricin A chain increases the cytotoxicity of the holotoxin.

L. Roberts, J. Lord, R. Wales, 1992, Experimental cell research.

Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications.

Anthony Scott-Tucker, C. Shone, J. Chaddock, 2005, Protein expression and purification.

A Conjugate Composed of Nerve Growth Factor Coupled to a Non-toxic Derivative of Clostridium botulinum Neurotoxin Type A can Inhibit Neurotransmitter Release in Vitro

C. Quinn, C. Shone, M. Duggan, 2000, Growth factors.

Isolation of the gene and large-scale expression and purification of recombinant Erythrina cristagalli lectin.

C. Shone, J. Chaddock, M. Matheson, 2003, Protein expression and purification.

Ricin A Chain Fused to a Chloroplast-targeting Signal Is Unfolded on the Chloroplast Surface Prior to Import across the Envelope Membranes (*)

Denise S Walker, L. Roberts, J. Lord, 1996, The Journal of Biological Chemistry.

Crystal structures of Erythrina cristagalli lectin with bound N-linked oligosaccharide and lactose.

R. Natesh, K. Acharya, N. Thiyagarajan, 2004, Glycobiology.

Major structural differences between pokeweed antiviral protein and ricin A-chain do not account for their differing ribosome specificity.

L. Roberts, J. Lord, A. Monzingo, 1996, European journal of biochemistry.

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity

J. Krupp, E. Fonfria, J. Chaddock, 2018, Toxins.

Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors

K. Acharya, G. Masuyer, J. Chaddock, 2015, Scientific Reports.

Future Developments: Engineering the Neurotoxin

John Chaddock, J. Chaddock, 2014 .

Inhibition of Vesicular Secretion in Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative ofClostridium botulinum Neurotoxin Type A

C. Quinn, C. Shone, M. Duggan, 2000, Infection and Immunity.

Targeted Secretion Inhibitors—Innovative Protein Therapeutics

K. Foster, J. Chaddock, 2010, Toxins.

Restoration of lectin activity to a non‐glycosylated ricin B chain mutant by the introduction of a novel N‐glycosylation site

Jinbiao Zhan, L. Roberts, J. Lord, 1997, FEBS letters.

Mutagenesis and kinetic analysis of the active site Glu177 of ricin A-chain.

L. Roberts, J. Chaddock, 1993, Protein engineering.

Chapter 57 – Clostridium botulinum and Associated Neurotoxins

J. Chaddock, M. Beard, 2015 .

Clostridium botulinum and Associated Neurotoxins

J. Melling, J. Chaddock, 2002 .

Engineered botulinum neurotoxins as new therapeutics.

G. Masuyer, J. Chaddock, Keith A. Foster, 2014, Annual review of pharmacology and toxicology.